Skip to main content
JDOC logo

JPMorgan Healthcare Leaders ETF (JDOC) Fund Overview

Educational signal · not a buy or sell recommendation · How to read this

$59.56 -$2.26 (-3.66%)
Vol: 40|

Beta 1.00: the stock has moved roughly in step with the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

JPMorgan Healthcare Leaders ETF (JDOC) trades at $59.56. Jpmorgan Healthcare Leaders ETF (JDOC) invests in leading pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology, and life sciences companies.

Price as of · Last analyzed: Mar 18, 2026
Jpmorgan Healthcare Leaders ETF (JDOC) invests in leading pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology, and life sciences companies. The fund aims to identify companies where the market undervalues their growth potential.

Analyst Coverage for JDOC: JDOC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

▶ Watch the JDOC film Every key number, told as a short cinematic story — just press play. ~2 min

JPMorgan Healthcare Leaders ETF Company Overview

Jpmorgan Healthcare Leaders ETF (JDOC) focuses on equity securities of healthcare companies, aiming to capitalize on market underestimation of their growth potential. The fund invests across pharmaceuticals, biotech, healthcare services, and related technology sectors, targeting industry leaders with sustainable growth prospects.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 18, 2026

What Is the Investment Thesis for JDOC?

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

The investment thesis for JDOC centers on the anticipated growth and innovation within the healthcare sector. The fund's strategy of investing in leading pharmaceutical, biotechnology, healthcare services, and medical technology companies positions it to benefit from advancements in healthcare and increasing demand for related services. Key value drivers include the aging global population, technological advancements in medicine, and increasing healthcare spending. Upcoming catalysts include potential breakthroughs in drug development and regulatory approvals. A potential risk is the impact of government regulations and healthcare policy changes on the profitability of healthcare companies. The fund's beta of 1.00 suggests market correlation.

Based on FMP financials and quantitative analysis

JDOC Key Highlights

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

JDOC invests at least 80% of its assets in the equity securities of healthcare companies.

  • The fund focuses on companies the adviser believes are leaders in the healthcare sector.
  • JDOC aims to identify companies where the magnitude and/or duration of future growth is underappreciated by the market.
  • The fund's investment universe includes pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology and life sciences companies.
  • JDOC has a beta of 1.00, indicating market correlation.

What Are JDOC's Key Strengths?

Focus on leading healthcare companies.

  • Potential for high growth in the healthcare sector.
  • Diversified portfolio within the healthcare industry.
  • Experienced investment team at JPMorgan.

What Are JDOC's Weaknesses?

Concentration in the healthcare sector.

  • Dependence on the performance of healthcare companies.
  • Potential for regulatory changes to impact the sector.
  • Vulnerability to market fluctuations.

What Are the Key Risks for JDOC?

Government regulations and healthcare policy changes impacting profitability.

  • Competition from other healthcare companies and ETFs.
  • Economic downturns reducing healthcare spending.
  • Patent expirations and generic drug competition affecting pharmaceutical companies.

What Are JDOC's Competitive Advantages?

  • Expertise in healthcare sector investing.
  • Access to JPMorgan's research and resources.
  • Diversified portfolio of leading healthcare companies.
  • Focus on identifying companies with underappreciated growth potential.

What Does JDOC Do?

Jpmorgan Healthcare Leaders ETF (JDOC) is designed to provide investors with exposure to leading companies within the healthcare sector. The fund's investment strategy centers on identifying pharmaceutical, biotechnology, healthcare services, healthcare technology, medical technology, and life sciences companies that exhibit strong leadership and significant growth potential that is not fully appreciated by the market. JDOC seeks to achieve its investment objective by primarily investing in equity securities of these healthcare companies, allocating at least 80% of its assets to this sector under normal circumstances. This concentrated approach allows the fund to focus on companies believed to be at the forefront of innovation and growth within the healthcare industry. The fund's portfolio construction reflects a conviction that these leading healthcare companies are poised to deliver superior returns as the market recognizes their true value and growth trajectory. The fund's investment decisions are guided by in-depth research and analysis, with the goal of constructing a portfolio that captures the most promising opportunities within the healthcare landscape.

What Products and Services Does JDOC Offer?

  • Invests in equity securities of healthcare companies.
  • Focuses on pharmaceutical companies.
  • Targets biotechnology companies.
  • Includes healthcare services companies.
  • Covers healthcare technology companies.
  • Invests in medical technology companies.
  • Includes life sciences companies.

How Does JDOC Make Money?

  • Invests in a diversified portfolio of healthcare companies.
  • Generates returns through capital appreciation of its holdings.
  • Aims to outperform its benchmark index.
  • Rebalances its portfolio periodically to maintain its investment strategy.

What Industry Does JDOC Operate In?

JDOC operates within the broader healthcare industry, which is characterized by continuous innovation, evolving regulations, and increasing demand driven by demographic shifts and technological advancements. The competitive landscape includes numerous specialized healthcare ETFs and mutual funds, each with its own investment strategy and focus. JDOC differentiates itself by targeting companies deemed to be leaders with underappreciated growth potential. The healthcare industry is expected to continue growing, driven by factors such as an aging global population and increasing healthcare spending.

Who Are JDOC's Key Customers?

  • Institutional investors.
  • Retail investors.
  • Financial advisors.
  • Retirement plans.
Model self-rating on this text: 64% (not a measure of the evidence) Updated: Mar 18, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
  • ● This is an etf, not an operating company

JDOC Financials

Bull Case vs Bear Case

Bull Case

  • Focus on leading healthcare companies.
  • Potential for high growth in the healthcare sector.
  • Diversified portfolio within the healthcare industry.
  • Experienced investment team at JPMorgan.

Bear Case

  • Concentration in the healthcare sector.
  • Dependence on the performance of healthcare companies.
  • Potential for regulatory changes to impact the sector.
  • Vulnerability to market fluctuations.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

JDOC Latest News

No recent news available for JDOC.

JDOC Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for JDOC.

Price Targets

Wall Street price target analysis for JDOC.

JDOC MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for JDOC; grades run from A+ (80-100) to F (below 30).

Common Questions About JDOC

What are the main risks for JDOC?

The primary risks associated with JDOC stem from its concentration in the healthcare sector. Government regulations and healthcare policy changes can significantly impact the profitability of companies within the portfolio.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • The healthcare sector is subject to regulatory and technological changes that may impact the fund's performance.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis